HK1017905A1 - Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways. - Google Patents

Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways.

Info

Publication number
HK1017905A1
HK1017905A1 HK99102918A HK99102918A HK1017905A1 HK 1017905 A1 HK1017905 A1 HK 1017905A1 HK 99102918 A HK99102918 A HK 99102918A HK 99102918 A HK99102918 A HK 99102918A HK 1017905 A1 HK1017905 A1 HK 1017905A1
Authority
HK
Hong Kong
Prior art keywords
induction
human
cell tolerance
binding
ligand
Prior art date
Application number
HK99102918A
Other languages
English (en)
Inventor
Mark De Boer
Original Assignee
Pangenetics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangenetics Bv filed Critical Pangenetics Bv
Publication of HK1017905A1 publication Critical patent/HK1017905A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Optical Measuring Cells (AREA)
HK99102918A 1996-07-23 1999-07-08 Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways. HK1017905A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2207096P 1996-07-23 1996-07-23
PCT/NL1997/000438 WO1998003670A1 (en) 1996-07-23 1997-07-23 Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways

Publications (1)

Publication Number Publication Date
HK1017905A1 true HK1017905A1 (en) 1999-12-03

Family

ID=21807674

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102918A HK1017905A1 (en) 1996-07-23 1999-07-08 Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways.

Country Status (8)

Country Link
US (1) US20020150559A1 (xx)
EP (1) EP0922111B1 (xx)
JP (1) JP4219985B2 (xx)
AT (1) ATE283925T1 (xx)
CA (1) CA2260752A1 (xx)
DE (1) DE69731836T2 (xx)
HK (1) HK1017905A1 (xx)
WO (1) WO1998003670A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8800598A (en) * 1997-06-20 1999-01-04 Innogenetics N.V. B7-binding molecules for treating immune diseases
WO1999039727A1 (en) * 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
FR2789089A1 (fr) * 1999-02-02 2000-08-04 Pf Medicament Lymphocytes t humains effecteurs exprimant la molecule cd86 et possedant des proprietes immunodulatrices, costimulatrices et cytotoxiques, leurs procedes d'obtention et leurs applications
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
CA2406961A1 (en) * 2000-04-19 2002-02-14 Tanox, Inc. Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
US20030059888A1 (en) * 2001-08-22 2003-03-27 Shengfeng Li Compositions and methods for generating antigen-binding units
US20070148162A1 (en) * 2003-02-27 2007-06-28 Ranjit Bhardwaj Molecule which binds cd80 and cd86
US20070009517A1 (en) * 2003-08-25 2007-01-11 Mark De Boer Method of inducing immune tolerance
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2195341B1 (en) * 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
EA201100527A1 (ru) * 2008-09-26 2011-10-31 Юсб Фарма С.А. Биологические продукты
EP2344540B1 (en) * 2008-10-02 2017-11-29 Aptevo Research and Development LLC Cd86 antagonist multi-target binding proteins
US20110217302A1 (en) * 2008-10-10 2011-09-08 Emergent Product Development Seattle, Llc TCR Complex Immunotherapeutics
AU2013249267A1 (en) 2012-04-20 2014-10-23 Aptevo Research And Development Llc CD3 binding polypeptides
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP2883883A1 (en) 2013-12-16 2015-06-17 Cardio3 Biosciences S.A. Therapeutic targets and agents useful in treating ischemia reperfusion injury
EP2930188A1 (en) * 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
EP3352760A4 (en) 2015-09-21 2019-03-06 Aptevo Research and Development LLC CD3 BINDING POLYPEPTIDES
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
CN108264561B (zh) * 2016-12-30 2021-09-10 惠和生物技术(上海)有限公司 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994013804A1 (en) * 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9412166D0 (en) * 1993-09-22 1994-08-10 Medical Res Council Retargetting antibodies
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40

Also Published As

Publication number Publication date
US20020150559A1 (en) 2002-10-17
WO1998003670A1 (en) 1998-01-29
EP0922111A1 (en) 1999-06-16
JP2000515374A (ja) 2000-11-21
DE69731836T2 (de) 2005-12-01
DE69731836D1 (de) 2005-01-05
CA2260752A1 (en) 1998-01-29
EP0922111B1 (en) 2004-12-01
JP4219985B2 (ja) 2009-02-04
ATE283925T1 (de) 2004-12-15

Similar Documents

Publication Publication Date Title
HK1017905A1 (en) Induction of T cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways.
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
AU4612093A (en) Soluble ligands for CD40
NZ333607A (en) Method of stimulating the immune system by transfecting dendritic cells
HK1016018A1 (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
AU3889399A (en) Vaccine delivery system
AU7856700A (en) Composition and method of cancer antigen immunotherapy
MY113428A (en) Hepatitis b vaccine
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
CA2290485A1 (en) Method for the production of non-immunogenic proteins
BR0309254A (pt) Uso de um anticorpo anti-ctla-4
NZ335749A (en) Formulation in the form of a patch for transcutaneous immunization comprising an antigen and an adjuvant
PL336580A1 (en) Fine-molecular compounds useful in treating inflammatory diseases
WO1995029236A3 (en) Lymphocyte activation antigens and antibodies thereto
AU1716297A (en) Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation
EP0920623A4 (en) BOR NEUTRON CAPTURE THERAPY USING PRE-TARGETING METHODS
EP0614355A4 (en) Antitumor vaccines.
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
EP0202642A3 (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
HK1057233A1 (en) Hybrid cells obtainable from antigen presenting cells

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100723